

LEGISLATIVE FISCAL OFFICE
Fiscal Note



Fiscal Note On: **HB 436** HLS 17RS 273

Bill Text Version: **REENGROSSED**

Opp. Chamb. Action:

Proposed Amd.:

Sub. Bill For.:

Date: May 31, 2017	8:14 AM	Author: TALBOT
Dept./Agy.: Board of Pharmacy		Analyst: Willis Brewer
Subject: Requires information regarding prescription drug prices		

DRUGS/PRESCRIPTION: RE NO IMPACT See Note Page 1 of 1
Requires drug manufacturers to provide information regarding prescription drug prices and establishes the Prescription Drug Review Committee within the Dept. of Insurance

Proposed law requires each drug manufacturer or pharmaceutical marketer who engages in any form of prescription drug marketing to a prescriber, his designee, or any member of his staff in La. to provide to the La. Board of Pharmacy no later than Jan. 1st, Apr. 1st, July 1st, and Oct. 1st of each calendar year the current wholesale acquisition cost information for the U.S. Food and Drug Administration approved drugs marketed in the state by that manufacturer.

Proposed law defines "prescription drug" and "prescription drug marketing".

EXPENDITURES	2017-18	2018-19	2019-20	2020-21	2021-22	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

REVENUES	2017-18	2018-19	2019-20	2020-21	2021-22	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

There is no anticipated direct material effect on governmental expenditures as a result of this measure.

Proposed law will require drug manufacturer or pharmaceutical marketer to submit to La Board of Pharmacy the current wholesale acquisition cost information for the U.S. Food and Drug Administration approved drugs marketed in the state by that manufacturer. The LFO anticipates any costs incurred by the Board of Pharmacy to receive this information will be minimal and can be absorbed within their budget.

While the proposed legislation does not specify what the Board of Pharmacy is required to do with this information, to the extent additional data collection, reporting, and analysis is required, the Board may incur additional expenses.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate Dual Referral Rules
 13.5.1 >= \$100,000 Annual Fiscal Cost {S&H}
 13.5.2 >= \$500,000 Annual Tax or Fee Change {S&H}

House
 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}
 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Evan Brasseaux

Evan Brasseaux
Staff Director